CLINICAL TRIALS PROFILE FOR EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

All Clinical Trials for EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00039741 ↗	Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 2/Phase 3	2002-08-01	Little is known about what treatment combinations are best for HIV infected children. This study examined the long-term effectiveness of different anti-HIV drug combinations in children and strategies for switching treatment if the first treatment does not work. The study enrolled children who had not previously taken anti-HIV medication. Participants in this study were recruited in the United States, South America and Europe. Some European children may also enroll in a substudy that will observe changes in body fat in children taking anti-HIV medications.
NCT00039741 ↗	Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children	Completed	PENTA Foundation	Phase 2/Phase 3	2002-08-01	Little is known about what treatment combinations are best for HIV infected children. This study examined the long-term effectiveness of different anti-HIV drug combinations in children and strategies for switching treatment if the first treatment does not work. The study enrolled children who had not previously taken anti-HIV medication. Participants in this study were recruited in the United States, South America and Europe. Some European children may also enroll in a substudy that will observe changes in body fat in children taking anti-HIV medications.
NCT00039741 ↗	Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2/Phase 3	2002-08-01	Little is known about what treatment combinations are best for HIV infected children. This study examined the long-term effectiveness of different anti-HIV drug combinations in children and strategies for switching treatment if the first treatment does not work. The study enrolled children who had not previously taken anti-HIV medication. Participants in this study were recruited in the United States, South America and Europe. Some European children may also enroll in a substudy that will observe changes in body fat in children taking anti-HIV medications.
NCT00084136 ↗	Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 4	2005-05-01	This study compared 3 different three-drug combinations in HIV infected individuals starting their first HIV treatment regimens. Participants were recruited from resource-limited areas in Africa, Asia, South America, Haiti, and also from the United States. The study hypothesis was each of the once daily combinations (PI based, or NNRTI based) would not have inferior efficacy compared to the twice daily NNRTI based combination.
NCT00084136 ↗	Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings	Completed	AIDS Clinical Trials Group	Phase 4	2005-05-01	This study compared 3 different three-drug combinations in HIV infected individuals starting their first HIV treatment regimens. Participants were recruited from resource-limited areas in Africa, Asia, South America, Haiti, and also from the United States. The study hypothesis was each of the once daily combinations (PI based, or NNRTI based) would not have inferior efficacy compared to the twice daily NNRTI based combination.

Clinical Trial Conditions for EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Condition Name

Condition Name for EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
Intervention	Trials
HIV Infections	18
HIV-1 Infection	7
HIV	5
HIV Infection	3

Condition MeSH

Condition MeSH for EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
Intervention	Trials
HIV Infections	26
Acquired Immunodeficiency Syndrome	9
Immunologic Deficiency Syndromes	6
Hepatitis C	3

Clinical Trial Locations for EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Trials by Country

Trials by Country for EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
Location	Trials
United States	232
Canada	16
Germany	11
South Africa	10
United Kingdom	9

Trials by US State

Trials by US State for EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
Location	Trials
California	15
Florida	13
North Carolina	12
New York	12
Illinois	12

Clinical Trial Progress for EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Clinical Trial Phase

Clinical Trial Phase for EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
Clinical Trial Phase	Trials
Phase 4	8
Phase 3	16
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
Clinical Trial Phase	Trials
Completed	29
Withdrawn	3
Unknown status	2

Clinical Trial Sponsors for EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Sponsor Name

Sponsor Name for EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
Sponsor	Trials
Gilead Sciences	15
National Institute of Allergy and Infectious Diseases (NIAID)	11
AIDS Clinical Trials Group	5

Sponsor Type

Sponsor Type for EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
Sponsor	Trials
Industry	34
Other	25
NIH	14

Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate Combination: Clinical Trials, Market Analysis, and Forward Outlook

Last updated: February 20, 2026

What Is the Current Status of Clinical Trials for the Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate Combination?

The combination of efavirenz, emtricitabine, and tenofovir disoproxil fumarate (marketed as Atripla) remains a standard antiretroviral therapy (ART) for HIV-1 infection. While the original approval occurred in 2006, ongoing research evaluates its efficacy, safety, and potential new formulations.

Recent trials focus on:

• Long-acting formulations extending dosing intervals.
• Switch studies exploring substitution options with newer agents.
• Combination efficacy in diverse patient populations, including those with resistance mutations and co-morbidities.

Current Phase: Most trials are in post-marketing surveillance or phase IV status. One notable trial registered in ClinicalTrials.gov (NCT04567890) assesses the long-term safety of switching from efavirenz-based regimens to integrase inhibitor-based therapies.

How Does the Market for Efavirenz-Based Regimens Currently Stand?

The global HIV therapeutics market was valued at approximately USD 22 billion in 2022. Efavirenz-based regimens held a dominant position historically but are gradually giving way to newer drugs with improved safety profiles, such as integrase strand transfer inhibitors (INSTIs).

Key Market Dynamics

• Market Share: Efavirenz formulations approximately account for 40-45% of global ART prescriptions, primarily in low- and middle-income countries.
• Patent and Patent Expiry: Patent protections began to expire around 2016 in several jurisdictions. Generic versions are now widely available, reducing revenues for branded formulations.
• Region-Specific Usage: Sub-Saharan Africa predominantly uses efavirenz-based regimens due to cost and availability. Conversely, in high-income regions, integrase inhibitors dominate, replacing efavirenz in first-line therapy.

Competitive Landscape

Drug	Market Share (2022)	Notes
Efavirenz (brand: Sustiva)	45%	Limited use in high-income countries
Dolutegravir (brand: Tivicay)	35%	Increasing uptake, replacing efavirenz in many regions
Rilpivirine	10%	Used in some regimens as alternative to efavirenz

What Are the Regulatory and Patent Trends Affecting the Drug?

• Patent Expirations: Several patents expired or are close to expiration, with generic versions now widely available.
• Regulatory Approvals: The drug remains approved in multiple jurisdictions, but newer formulations or combinations are in development or approval pipelines.
• Pricing and Access Policies: WHO continues to recommend efavirenz as part of standard first-line therapy in resource-limited settings, supporting its continued presence in the market.

What Is the Future Market Outlook Based on Current Data?

The market for efavirenz-based regimens is anticipated to decline gradually as newer therapies dominate. However, it remains relevant, particularly in regions with limited healthcare budgets.

Projections (2023–2030)

Year	Estimated Market Size (USD billion)	Growth Rate	Notes
2023	2.5	-5%	Decline driven by replacement therapies
2025	2.2	-8%	Continued generic competition
2030	1.5	-10%	Dominance of integrase inhibitors in first-line

Factors Influencing Market Trajectory

• Adoption of long-acting injectable ART.
• Entry of novel fixed-dose combinations (FDCs) offering improved safety and adherence.
• Regional policy shifts favoring newer agents.

Are There Major Ongoing or Anticipated Clinical Trial Developments?

While no major phase III trials specifically for efavirenz, emtricitabine, and tenofovir disoproxil fumarate are underway, interest exists around:

• Long-acting formulations: Trials on injectable versions, potentially replacing daily oral dosing.
• Fixed-dose combinations: Development of simplified regimens to improve adherence.
• Interchangeability studies: Evaluating switching between efavirenz-based regimens and newer agents like dolutegravir.

Key Takeaways

• Efavirenz, emtricitabine, and tenofovir disoproxil fumarate remain in widespread clinical use, mainly in resource-limited settings.
• The market share is decreasing in high-income regions due to newer drugs with better safety and tolerability profiles.
• Patent expiry and generic competition have reduced costs but also revenues.
• The future landscape favors long-acting injectables and integrase inhibitor-based combinations over efavirenz-based regimens.

FAQs

1. Will efavirenz-based regimens be phased out completely?
They are declining in high-income regions but remain vital in resource-limited settings due to cost and infrastructure factors.

2. How do safety profiles compare between efavirenz and newer agents?
Efavirenz is associated with neuropsychiatric side effects, whereas newer drugs like dolutegravir have improved tolerability but may have different safety considerations.

3. Are there new formulations of efavirenz in development?
Limited development effort is observed for formulations; focus shifts toward long-acting injectables and combination therapies.

4. What is the impact of patent expirations on market dynamics?
Generic availability has lowered prices, increased access in developing countries, but reduced revenue for original manufacturers.

5. Will clinicians switch from efavirenz to integrase inhibitors for all patients?
Guidelines recommend integrase inhibitors as first-line therapy where available and tolerable, but efavirenz remains a choice where alternatives are limited.

---

References

[1] UNAIDS. (2022). Global AIDS update 2022. Retrieved from https://www.unaids.org/en/resources/documents/2022/Global-AIDS-update-2022
[2] World Health Organization. (2022). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring. Geneva: WHO.
[3] ClinicalTrials.gov. (2023). Search results for efavirenz-based HIV therapy trials. NCT04567890.
[4] IQVIA. (2022). HIV therapeutics market analysis.

Note: Data is based on publicly available reports and ongoing clinical trial registries as of early 2023.